Allspring Global Investments Holdings LLC Sells 424 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Allspring Global Investments Holdings LLC lowered its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 0.9% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 45,438 shares of the specialty pharmaceutical company’s stock after selling 424 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Collegium Pharmaceutical were worth $1,764,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Principal Securities Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $40,000. China Universal Asset Management Co. Ltd. grew its holdings in Collegium Pharmaceutical by 320.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after buying an additional 2,877 shares in the last quarter. Assetmark Inc. grew its holdings in Collegium Pharmaceutical by 25.5% during the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock worth $168,000 after buying an additional 1,108 shares in the last quarter. Johnson Investment Counsel Inc. bought a new stake in Collegium Pharmaceutical during the fourth quarter worth $257,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Collegium Pharmaceutical by 28.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,841 shares of the specialty pharmaceutical company’s stock worth $272,000 after buying an additional 1,967 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently issued reports on COLL shares. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, May 1st. Piper Sandler cut Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 price objective on the stock. in a research report on Friday, May 10th. Needham & Company LLC cut Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Finally, Jefferies Financial Group raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $40.75.

Collegium Pharmaceutical Stock Up 1.0 %

COLL stock opened at $32.36 on Thursday. Collegium Pharmaceutical, Inc. has a 1-year low of $20.83 and a 1-year high of $40.95. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The stock’s fifty day simple moving average is $33.64 and its two-hundred day simple moving average is $34.40. The stock has a market cap of $1.06 billion, a P/E ratio of 13.48 and a beta of 0.93.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.04). Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The firm had revenue of $144.92 million for the quarter, compared to analysts’ expectations of $147.04 million. Analysts expect that Collegium Pharmaceutical, Inc. will post 5.57 EPS for the current year.

Insider Activity

In other news, Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total transaction of $936,215.50. Following the transaction, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, CFO Colleen Tupper sold 19,710 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Garen G. Bohlin sold 28,985 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total value of $936,215.50. Following the sale, the director now directly owns 44,775 shares in the company, valued at approximately $1,446,232.50. The disclosure for this sale can be found here. Insiders have sold 105,502 shares of company stock valued at $3,540,796 in the last 90 days. Insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.